SCHEMBL22216571

SCHEMBL22216571

CCOC(=O)C(Cc1ccccc1)(OC[C@H](C)OC)C(=O)OCC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
MMP8 P22894 2/20 0.48
RECQL P46063 1/20 0.48
PIN1 Q13526 2/20 0.40
PTPN2 P17706 2/20 0.39
PTPN1 P18031 2/20 0.39
PTPRB P23467 2/20 0.39
ACP1 P24666 1/20 0.39
LMNA P02545 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
POLB P06746 2/20 0.37
PPID Q08752 1/20 0.37
HSD17B10 Q99714 1/20 0.37
PTPRA P18433 1/20 0.37
TAAR1 Q96RJ0 2/20 0.36
THRB P10828 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TDP1 Q9NUW8 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22216498 0.85 SMN1; SMN2 (0.41) ALDH1A1MMP8RECQLPTPN2PTPN1
SCHEMBL20350547 0.85 ALDH1A1 (0.46) ALDH1A1MMP8RECQLPIN1PTPN2
SCHEMBL16865453 0.83 ALDH1A1 (0.57) ALDH1A1MMP8RECQLPIN1PTPN2
SCHEMBL7431853 0.80 ALDH1A1 (0.57) ALDH1A1MMP8RECQLPIN1PTPN2
SCHEMBL20350605 0.75 MMP8 (0.58) ALDH1A1MMP8RECQLPIN1PTPN2
SCHEMBL6740786 0.73 ALDH1A1 (0.56) ALDH1A1MMP8RECQLPIN1LMNA
SCHEMBL9199837 0.73 ALDH1A1 (0.47) ALDH1A1MMP8RECQLPIN1PTPN2
SCHEMBL20333385 0.72 MMP8 (0.56) ALDH1A1MMP8RECQLPIN1PTPN2
SCHEMBL10821760 0.72 MMP8 (0.63) ALDH1A1MMP8RECQLPIN1LMNA
SCHEMBL4419400 0.72 ALDH1A1 (0.62) ALDH1A1MMP8RECQLPIN1PTPN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11034715-B2 Ectonucleotidase inhibitors and methods of use thereof CALITHERA BIOSCIENCES, INC. (US) 2021-06-15 US disclosed
US-20200223882-A1 Ectonucleotidase Inhibitors and Methods of Use Thereof ANTENGENE THERAPEUTICS LIMITED (CN) 2020-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200223882-A1 Ectonucleotidase Inhibitors and Methods of Use Thereof NT5E, ENTPD5, NT5C2 ALDH1A1 527/4885MMP8 214/4885RECQL 644/4885
US-11034715-B2 Ectonucleotidase inhibitors and methods of use thereof NT5E, ENTPD5, NT5C2 ALDH1A1 527/4885MMP8 214/4885RECQL 644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.